Relevant bibliographies by topics / Rehab Basel (Basel, Switzerland) / Journal articles

Journal articles on the topic 'Rehab Basel (Basel, Switzerland)'

To see the other types of publications on this topic, follow the link: Rehab Basel (Basel, Switzerland).
Author: Grafiati
Published: 26 July 2024
Last updated: 27 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Rehab Basel (Basel, Switzerland).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Okujava, Rusudan, Fernando Garcia-Alcalde, Andreas Haldimann, Claudia Zampaloni, Ian Morrissey, Sophie Magnet, Nimmi Kothari, Ian Harding, and Kenneth Bradley. "1359. Activity of Meropenem/Nacubactam Combination Against Gram-Negative Clinical Isolates: ROSCO Global Surveillance 2017." Open Forum Infectious Diseases 5, suppl_1 (November 2018): S416. http://dx.doi.org/10.1093/ofid/ofy210.1190.

Full text
Abstract:
Abstract Background Nacubactam (NAC, OP0595, RG6080) is a novel member of the diazabicyclooctane inhibitor family with a dual mode of action, acting as a β-lactamase inhibitor and an antibacterial agent by means of PBP2 inactivation. NAC restores and extends the activity of β-lactam antibiotics, such as meropenem (MEM), when used in combination against a variety of carbapenem-resistant Enterobacteriaceae (CRE). The first year results of the ROSCO surveillance study for MEM/NAC against contemporary clinical isolates are presented here. Methods Isolates (n = 4,695) collected in 2017 from 50 sites in the United States and European hospitals included 30 different species of Enterobacteriaceae (EB, n = 3,306), Pseudomonas spp. (n = 960) and Acinetobacter spp. (n = 429). The predominant species of EB are shown in figure below. MICs were determined by broth microdilution following CLSI methodology for MEM/NAC at a fixed 1:1 ratio (w:w) and by titrating MEM with a constant concentration of NAC at 4 mg/L. Results were compared with MIC values of MEM and NAC alone and standard of care antibiotics, including ceftazidime/avibactam (CAZ/AVI). Results MIC50/90 for MEM, NAC, and MEM/NAC against all EB isolates and by species are shown in the figure below. NAC alone displayed a bimodal MIC distribution for EB, with a prominent separation at ≤4 mg/L. MEM/NAC 1:1 inhibited 99.5, 99.7, and 99.9% of the 3,306 EB isolates tested, at ≤2, ≤4, and ≤8 mg/L, respectively; while MEM inhibited 96.5, 96.8, and 97.3% of the isolates at the same concentrations. Of 117 (3.5% of total EB) MEM nonsusceptible (by EUCAST) and multidrug resistant (MDR, by Magiorakos AP, et al., 2012) EB, 87.2, 92.3, and 96.6% were inhibited by MEM/NAC 1:1 at ≤2, ≤4, and ≤8 mg/L, respectively. Additionally, MEM/NAC1:1 displayed MIC ≤8 mg/L for 33 out of 37 CAZ/AVI-resistant MDR EB isolates. MEM/NAC had a similar activity to MEM alone against Pseudomonas spp. and Acinetobacter spp. Conclusion MEM/NAC combination shows excellent in vitro activity against current clinical EB isolates and the potential to extend MEM activity to MDR, MEM nonsusceptible and CAZ/AVI-resistant isolates, which supports the continued clinical development of MEM/NAC for infections caused by CREs. This project has been funded in part under HHS BARDA Contract HHSO100201600038C. Disclosures R. Okujava, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Employee, Salary. F. Garcia-Alcalde, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Employee, Salary. A. Haldimann, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Employee, Salary. C. Zampaloni, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Employee, Salary. I. Morrissey, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Research Contractor, Contracting fee to IHMA. S. Magnet, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Research Contractor, Contracting fee to IHMA. N. Kothari, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Research Contractor, Contracting fee to IHMA. I. Harding, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Research Contractor, Contracting fee to Micron. K. Bradley, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland: Employee, Salary.
APA, Harvard, Vancouver, ISO, and other styles
2

YOSHIKAWA, Genki. "Two Years in Basel, Switzerland." Hyomen Kagaku 34, no. 2 (2013): 92–93. http://dx.doi.org/10.1380/jsssj.34.92.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gewin, Virginia. "Erich Nigg, director of the Biozentrum, University of Basel, Basel, Switzerland." Nature 456, no. 7221 (November 2008): 542. http://dx.doi.org/10.1038/nj7221-542a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Fromm, Katharina M., and Jürg Schefer. "European Crystallographic Meeting in Basel, Switzerland." Neutron News 28, no. 2 (April 3, 2017): 4–5. http://dx.doi.org/10.1080/10448632.2017.1307064.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Willi, Patrik O., Dominic T. Egger, and Chantal S. Balmer. "Switzerland at the International Chemistry Olympiad 2022." CHIMIA 76, no. 10 (October 26, 2022): 876. http://dx.doi.org/10.2533/chimia.2022.876.

Full text
Abstract:
At the remote International Chemistry Olympiad 2022 hosted by China, two outstanding students from Switzerland won one bronze medal and one honorable mention. A joint remote participation to the event of the delegations from Germany, Austria, and Switzerland could be realized in Basel with the support of the University of Basel. The International Chemistry Olympiad 2023 will be hosted at ETH Zurich. This itinerary will mark the first time this annual event comes to Switzerland.
APA, Harvard, Vancouver, ISO, and other styles
6

Brugnara, Carlo, Anja Harmeier, Lucia De Franceschi, Alessandro Matte, Michael Winter, Annette Koerner, Omar Khwaja, et al. "A Selective ORAL GLYT1 Inhibitor, Improves Anemia and RED CELL Survival in a MOUSE MODEL of Beta-Thalassemia." Blood 128, no. 22 (December 2, 2016): 1284. http://dx.doi.org/10.1182/blood.v128.22.1284.1284.

Full text
Abstract:
Abstract The unbalanced hemoglobin chain synthesis in beta-thalassemias leads to hemichrome-induced damage that contributes to ineffective erythropoiesis, hemolysis and reduced red cell survival. Iron overload related to ineffective erythropoiesis and abnormally low Hepcidin (Hamp), combined with the cytotoxic effects of free heme with free-alpha-chains play a key role in the increased generation of reactive oxygen species (ROS) in beta thalassemias.[2][HA{3] Here we used a specific and selective inhibitor of the plasma membrane expressed glycine transporter GlyT1 (Ro4917838). Use of Ro4917838 has been associated with a dose-dependent decrease in MCH, Hb, soluble transferrin receptor, and increase in absolute reticulocytes and RBC counts in several animal species, attributed to reduce glycine bioavailability in erythroblasts and decreased heme synthesis. In rats, Ro4917838 reduces heme synthesis, and down-regulates erythroid transferrin receptor, but does not interfere with hepcidin regulation and systemic iron homeostasis (Winter et al. Exp Hematol, DOI: 10.1016/j.exphem.2016.07.003). We aimed to determine if reduced cellular availability of glycine in erythroblasts may reduce heme synthesis, and impact pathologic erythropoiesis in a mouse model for b-thalassemia. Wild-type control (WT) C57B6/2J, and beta-thalassemia Hbbth3/+ mice were treated with either vehicle or Ro4917838 at dosages of 3, 10, 30 mg/kg/d administered over 4 weeks once daily by gavage. [6]RO4917838 administration was associated with significant improvements of central hallmarks of the b-thalassemia pathology. Reduced erythrocyte destruction was seen bydemonstrated by [8][WM{9]as significant improvements in erythrocyte morphology and amelioration of hemoglobin reduction in reticulocytes. We also observed an impressively quick reduction of the circulating erythroblast count within 1 week of initiating treatment. This was also associated with decreased hemolysis biomarkers. Ro4917838 induced a significant reduction in extramedullary erythropoiesis and reduction in orthochromatic erythroblasts as well as insoluble alpha chain aggregates in circulating red cells. Red cell survival of b-thal mice treated with 30 mg/kg/day Ro4917838 significantly increased by more than 50%. CD71+ erythroid precursors significantly decreased in WT mice treated with Ro4917838 at 30 mg/kg and in b-thal mice at the dosage of 30 mg/kg/ d. [10]These data suggest that Ro4917838 ameliorates anemia in a b-thalassemia mouse model and positively affects ineffective erythropoiesis and red cell survival in peripheral circulation. Ro4917838 may represent a novel therapeutic approach for the treatment of anemia in b-thalassemia patients. [1] I do see the point for beta-thalassemia, but this does not apply for all thalassemias, I mean the free alpha chains. The ROS yes, they have in common. In this sentence it seems to be that the alpha chains are culprit for ROS in all thalassemias. [HA{3]I do see the point for beta-thalassemia, but this does not apply for all thalassemias, I mean the free alpha chains. The ROS yes, they have in common. In this sentence it seems to be that the alpha chains are culprit for ROS in all thalassemias. ROS was not measured, therefore I would refrain mentioning it. No data is shown. [HA{5]ROS was not measured, therefore I would refrain mentioning it. No data is shown. I propose deletion of the PK info. Although the information is correct I don't think this is the level of detail needed for the abstract. It may even be confusing as it is not the focus of the abstract to do a cross species comparison. [AK7]I propose deletion of the PK info. Although the information is correct I don't think this is the level of detail needed for the abstract. It may even be confusing as it is not the focus of the abstract to do a cross species comparison. Dosing and dosing frequency is already described above, we do not need to repeat this here. [WM{9]Dosing and dosing frequency is already described above, we do not need to repeat this here. Was the liver expression determined or the serum Hepcidin levels measured? I would rephrase it if latter is the case. [HA{11]Was the liver expression determined or the serum Hepcidin levels measured? I would rephrase it if latter is the case. Disclosures Brugnara: F. Hoffmann-La Roche Ltd, Basel, Switzerland: Consultancy. Harmeier:F. Hoffmann-La Roche Ltd, Basel, Switzerland: Employment. De Franceschi:F. Hoffmann-La Roche Ltd, Basel, Switzerland: Research Funding. Matte:F. Hoffmann-La Roche Ltd, Basel, Switzerland: Research Funding. Winter:F. Hoffmann-La Roche Ltd, Basel, Switzerland: Employment. Koerner:F. Hoffmann-La Roche Ltd, Basel, Switzerland: Employment. Khwaja:F. Hoffmann-La Roche Ltd, Basel, Switzerland: Employment. Singer:F. Hoffmann-La Roche Ltd, Basel, Switzerland: Employment. Beneduce:Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland: Research Funding. Federti:Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland: Research Funding. Siciliano:Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland: Research Funding.
APA, Harvard, Vancouver, ISO, and other styles
7

Podavka, Ondřej. "Ladislav Velen of Žerotín and his Study Stay in Switzerland." AUC HISTORIA UNIVERSITATIS CAROLINAE PRAGENSIS 63, no. 1 (February 14, 2024): 203–12. http://dx.doi.org/10.14712/23365730.2023.30.

Full text
Abstract:
This contribution focuses on Ladislav Velen of Žerotín, member of an important Moravian family, and his stay in Basel between April 1592 and December 1593. His experiences from that time are described in Žerotín’s Itinerarium, which he wrote in 1589‒1594. After presenting some introductory information about this literary source and its writer, the author investigates contacts which Žerotín established during his studies in Basel, events he describes in the Itinerarium, and trips from Basel, which belong to the most detailed records in this diary. They depict his impression of the places he visited ‒ be it military facilities, ecclesiastic buildings, workshops, or other objects – but also the surrounding landscape and unforeseen events Žerotín encountered during his travels.
APA, Harvard, Vancouver, ISO, and other styles
8

Nickel, CHl. "Exploring the value of routinely measured hematology parameters for identification of elderly patients at high risk of death at the Emergency Department." Acute Medicine Journal 17, no. 4 (October 1, 2018): 177. http://dx.doi.org/10.52964/amja.0728.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Grigore, Elena, Norman Garrick, Raphael Fuhrer, and Ing Kay W. Axhausen. "Bikeability in Basel." Transportation Research Record: Journal of the Transportation Research Board 2673, no. 6 (April 12, 2019): 607–17. http://dx.doi.org/10.1177/0361198119839982.

Full text
Abstract:
“Bikeability” is becoming increasingly relevant in the field of transport- and urban planning. However, it is often unclear how bikeability is defined, let alone how it can be modeled. The goal of this project was to develop a quantitative method to model bikeability. A case study area in the city of Basel, Switzerland was selected for assessing the model. Here “bikeability” is understood as a measure of the ability and convenience in reaching important destinations by bike, based on the travel distance weighted by the perceived safety, -comfort, and -attractiveness of the streets and intersections along the routes. The underlying assumption was that cyclists try to minimize the distance traveled and maximize the perceived safety, -comfort, and -attractiveness of their route of choice. Unlike most of the previous bikeability assessments we reviewed, our method used existing route choice studies to identify attributes for quantifying cycling quality, which presumably results in a model that more accurately reflects real-life behavior. Many relevant attributes that have not been captured by previous models are included in this work, such as the high curbs of tram stops, tram tracks, and the turn direction at intersections. The method is suitable for several applications in urban planning, such as the identification of locations that need improvement and the comparison of planning measures. The current model covers conventional bikes used by commuting cyclists. However, the method could be used for E-bikes and non-commuting cyclists by applying the appropriate input values.
APA, Harvard, Vancouver, ISO, and other styles
10

Nishimura, Jun-ichi, Antoine Soubret, Simon Buatois, Jean-Eric Charoin, Sasha Sreckovic, Christoph Bucher, Jules Hernández-Sánchez, et al. "An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial." Blood 136, Supplement 1 (November 5, 2020): 2–3. http://dx.doi.org/10.1182/blood-2020-136265.

Full text
Abstract:
Introduction Crovalimab is a novel anti-complement component 5 (C5) monoclonal antibody engineered with the Sequential Monoclonal Antibody Recycling Technology (SMART-Ig; Fukuzawa et al, Sci Rep. 2017) to extend half-life and enable infrequent, subcutaneous (SC) self-administration in C5-mediated diseases. Crovalimab is being investigated as a therapy for paroxysmal nocturnal hemoglobinuria (PNH), a disease for which C5 inhibition is the standard of care. The Phase I/II COMPOSER trial (NCT03157635; Röth, et al. Blood. 2020) is a global, open-label, multicenter study of crovalimab consisting of 4 sequential parts. Parts 1, 2, and 3 assessed the pharmacokinetics (PK) and safety of crovalimab in healthy volunteers, C5 inhibitor-naive patients, and patients switched from eculizumab, respectively. Part 4 assessed an optimized crovalimab dose and regimen in naive and switched patients with PNH. Because eculizumab and crovalimab bind to different C5 epitopes, drug-target-drug complexes (DTDCs) consisting of eculizumab, C5, and crovalimab motifs can temporarily form in the circulation of patients who switch treatments. DTDCs can form in a range of sizes, from single crovalimab-C5-eculizumab motif to larger complexes with multiple motifs. Larger DTDCs are a concern because they take longer to clear and may be more likely to induce type III hypersensitivity reactions. Objectives Describe the impact of DTDC formation on the safety, PK, and pharmacodynamics of crovalimab in patients with PNH who switched from eculizumab to crovalimab and to describe the effect of crovalimab dose on DTDC size distribution and kinetics. Study Design and Methods Using data from COMPOSER Parts 1-3, a biochemical mathematical model was developed to investigate the kinetics of the formation and dissociation of DTDCs under the assumption that larger complexes are formed by the reversible binding of smaller complexes. The model was calibrated using concentration-time profiles of total C5, total crovalimab, and the concentration of eculizumab at the time of crovalimab initiation. DTDC size distributions were measured using size-exclusion chromatography coupled to enzyme-linked immunosorbent assay. Using model-based simulations, an optimized crovalimab dosing strategy was identified to reduce the formation of large DTDCs while maintaining serum concentration of crovalimab above the target level of ≈ 100 μg/mL. The optimized dose and regimen were a loading series of 1000 mg intravenously on day 1 and 340 mg SC on days 2, 8, 15, and 22, followed by maintenance dosing of 680 mg SC every 4 weeks starting on day 29. The loading dose series increased the total crovalimab dose received during the first month of treatment to reduce the formation of larger DTDCs, in line with the lattice theory of complex formation. This optimized dosing strategy was investigated in Part 4 patients who switched from eculizumab. Results In COMPOSER, 19 patients with PNH were enrolled in Part 3 and switched from eculizumab to crovalimab. DTDCs were observed in all patients from Part 3 (Figure; larger DTDCs are found in fractions 1-4 and smaller crovalimab-containing complexes, such as single motifs and single crovalimab molecules, are found in fractions 5 and 6). Two Part 3 patients experienced clinical manifestations compatible with type III hypersensitivity reactions that were ascribed to DTDCs. The DTDC size distribution in Part 4 patients, who received the optimized dosing strategy, evolved differently than in Part 3 patients, consistent with model predictions. In the switched patients from Part 4, large DTDC levels started to decrease on day 8 and continued to decrease, in contrast to Part 3, in which they started to decrease on day 15. On day 22, the mean percentage of the largest DTDCs was reduced by 56% in patients in Part 4 relative to patients in Part 3. Part 4 patients achieved and maintained serum crovalimab concentrations above ≈ 100 µg/mL throughout follow-up. Despite DTDCs being observed in all Part 4 patients who switched from eculizumab, no adverse events suggestive of a type III hypersensitivity reaction occurred. Conclusions The optimized crovalimab regimen resulted in lower concentrations of large DTDCs than in patients who received the Part 3 regimen and reduced the persistence of DTDCs in patients who switched treatment. This regimen is now being evaluated in the Phase III COMMODORE 1 (NCT04432584) and COMMODORE 2 (NCT04434092) studies. Figure Disclosures Nishimura: F. Hoffmann-La Roche Ltd: Consultancy, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.; Alexion: Honoraria, Research Funding; Chugai: Consultancy. Soubret:F. Hoffmann-La Roche Ltd: Current Employment, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Buatois:F. Hoffmann-La Roche Ltd: Current Employment, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Charoin:F. Hoffmann-La Roche Ltd: Current Employment, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Sreckovic:F. Hoffmann-La Roche Ltd: Current Employment, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Bucher:F. Hoffmann-La Roche Ltd: Current equity holder in publicly-traded company, Ended employment in the past 24 months, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.; ANAVEON AG: Current Employment. Hernández-Sánchez:F. Hoffmann-La Roche Ltd: Current Employment, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Jordan:F. Hoffmann-La Roche Ltd: Current Employment, Current equity holder in publicly-traded company, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Ramos:F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.; Genentech, Inc: Current Employment, Other: Received fellowship support from Genentech, Inc.. Arase:Osaka University: Current Employment; Chugai: Consultancy; Alexion: Research Funding; F. Hoffmann-La Roche. Ltd.: Consultancy, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Hotta:F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Isaka:Osaka University: Current Employment; Chugai: Research Funding, Speakers Bureau; F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Ito:F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Kanakura:F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.; Chugai Pharmaceutical: Consultancy. Kim:Alexion Pharmaceuticals Inc.: Honoraria, Research Funding. Kinoshita:Alexion: Honoraria; F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Morii:F. Hoffmann-La Roche Ltd: Honoraria, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland., Research Funding; Chugai: Honoraria, Research Funding. Panse:Apellis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Blueprint Medicines: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Chugai: Speakers Bureau; Grunenthal: Consultancy, Membership on an entity's Board of Directors or advisory committees; F. Hoffmann-La Roche Ltd: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; MSD: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Speakers Bureau; Alexion: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Boehringer Ingelheim: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Peffault De Latour:Alexion Pharmaceuticals Inc.: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Apellis: Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Amgen: Research Funding. Röth:Apellis: Consultancy, Honoraria; Alexion Pharmaceuticals Inc.: Consultancy, Honoraria, Research Funding; Biocryst: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria. Schrezenmeier:Alexion Pharmaceuticals Inc.: Honoraria, Research Funding. Sica:F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland., Research Funding. Takamori:Alexion: Research Funding; F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Ueda:Chugai: Research Funding; Novartis: Honoraria; Alexion: Consultancy, Honoraria, Research Funding; F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.; Sanofi: Consultancy, Honoraria. Yoon:Kyowahako Kirin: Research Funding; Novartis: Consultancy, Honoraria; Janssen: Consultancy; F. Hoffmann-La Roche: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland., Research Funding; YuhanPharma: Research Funding; Amgen: Consultancy, Honoraria. Paz-Priel:Genentech, Inc: Current Employment; F. Hoffmann-La Roche Ltd: Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Sostelly:F. Hoffmann-La Roche Ltd: Current Employment, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland..
APA, Harvard, Vancouver, ISO, and other styles
11

Glanzmann, Isabelle, Angela Klaiber, Muriel Perron, and Anne Freitag. "Die Verbreitung der Waldameisen in den Kantonen Basel-Landschaft und Basel-Stadt." Schweizerische Zeitschrift fur Forstwesen 170, no. 1 (January 1, 2019): 24–31. http://dx.doi.org/10.3188/szf.2019.0024.

Full text
Abstract:
Distribution of forest ants in the cantons of Basel-Landschaft and Basel-Stadt In 2015 and 2016, the forest service of the two Basel cantons and the nature protection service of Basel-Landschaft made an inventory of the distributions of forest ants, by mapping systematically the location of anthills. In total, 1757 anthills were found, which is estimated at two thirds of the real number of anthills. The presence of five species of domestic forest ants was demonstrated. The two most common species, Formica rufa and F. polyctena are mostly at medium altitude in Basel-Landschaft. As expected the nests of F. lugubris and F. paralugubris are found overwhelmingly at high altitude. The anthills of F. pratensis are mostly found in open habitats. The know ledge obtained through this mapping on the distribution of these species will make possible a targeted approach to protecting the nests. In addition, these results will serve as a baseline for future research, and represent a significant contribution to knowledge of fauna in Switzerland.
APA, Harvard, Vancouver, ISO, and other styles
12

Martínez Cantón, Clara, Petr Plecháč, Pablo Ruiz Fabo, and Levente Seláf. "Plotting Poetry: On mechanically enhanced reading, 5–7 October 2017, Basel, Switzerland." Studia Metrica et Poetica 4, no. 2 (January 4, 2018): 126–37. http://dx.doi.org/10.12697/smp.2017.4.2.05.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Roth, Peter. "Publisher’s Note: Welcome to Dermatopathology—A New Society Journal at MDPI Publishers." Dermatopathology 7, no. 1 (June 30, 2020): 17. http://dx.doi.org/10.3390/dermatopathology7010003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Liep, Hinde. "Ecochem 2014 (Basel, Switzerland, November 11–13, 2014)." Green Processing and Synthesis 3, no. 2 (April 1, 2014): 169–70. http://dx.doi.org/10.1515/gps-2014-0018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Ari, Asim. "A Good Start in Education, Switzerland Basel Kindergartens." International Journal of Instruction 16, no. 1 (January 1, 2023): i—vi. http://dx.doi.org/10.29333/iji.2023.1610a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Frank, U., C. Czepluch, H. Sticher, F. Mätzener, W. Schlaegel, and M. Mäder. "Modifiziertes Trachealkanülenmanagement: Platzhaltereinsatz als Option bei erschwerten Dekanülierungen (Pilotprojekt REHAB Basel)." Die Rehabilitation 52, no. 01 (July 3, 2012): 20–26. http://dx.doi.org/10.1055/s-0032-1306290.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Arnet, Isabelle, Pascal C. Baumgartner, Vera Bernhardt, Markus L. Lampert, and Kurt E. Hersberger. "Lessons Learned From Three Months of Pharmaceutical-Care Digital-Education at the University of Basel, Switzerland." Senior Care Pharmacist 35, no. 11 (November 1, 2020): 479–81. http://dx.doi.org/10.4140/tcp.n.2020.479.

Full text
Abstract:
An acceptable degree of digital literacy has always been present among the pharmacy teaching staff in Basel, with PowerPoint being the main vehicle to present teaching materials in front of full or half classes. Because cell phones became inseparable from students over the past years, mobile voting (movo.ch) or e-quizzes (mentimeter.com) have been regularly used to hold the attention of all students during collective teaching. Moreover, e-assessment on iPad® with the software BeAxi (www.k2prime.com) was introduced in 2012 and is currently used for all evaluations and exams. Suddenly over the night of March 16, 2020, our university, as all universities around the world, had to transfer all courses to an online format and to empower lecturers to teach from their home. This paper offers one perspective for how this digitial experiment unfolded at the University of Basel in Basel, Switzerland.
APA, Harvard, Vancouver, ISO, and other styles
18

Arnet, Isabelle, Pascal C. Baumgartner, Vera Bernhardt, Markus L. Lampert, and Kurt E. Hersberger. "Lessons Learned From Three Months of Pharmaceutical-Care Digital-Education at the University of Basel, Switzerland." Senior Care Pharmacist 35, no. 11 (November 1, 2020): 479–81. http://dx.doi.org/10.4140/tcp.n.2020.479.

Full text
Abstract:
An acceptable degree of digital literacy has always been present among the pharmacy teaching staff in Basel, with PowerPoint being the main vehicle to present teaching materials in front of full or half classes. Because cell phones became inseparable from students over the past years, mobile voting (movo.ch) or e-quizzes (mentimeter.com) have been regularly used to hold the attention of all students during collective teaching. Moreover, e-assessment on iPad® with the software BeAxi (www.k2prime.com) was introduced in 2012 and is currently used for all evaluations and exams. Suddenly over the night of March 16, 2020, our university, as all universities around the world, had to transfer all courses to an online format and to empower lecturers to teach from their home. This paper offers one perspective for how this digitial experiment unfolded at the University of Basel in Basel, Switzerland.
APA, Harvard, Vancouver, ISO, and other styles
19

Auberson, Yves P., and Martin Missbach. "Perspectives and Opportunities in Medicinal Chemistry: A View from the Novartis Institute for BioMedical Research Institute in Basel, Switzerland." CHIMIA 75, no. 12 (December 29, 2021): 1091. http://dx.doi.org/10.2533/chimia.2021.1091.

Full text
Abstract:
An opinion on changes and opportunities for the pharmaceutical industry in Switzerland, as seen from the Global Discovery Chemistry platform of the Novartis Institutes for BioMedical Research in Basel.
APA, Harvard, Vancouver, ISO, and other styles
20

Ari, Asim, and Simon Thiriet. "Switzerland Basel-Stadt Schools where every Student is Valuable." International Journal of Instruction 15, no. 3 (July 1, 2022): i—iii. http://dx.doi.org/10.29333/iji.2022.1530a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Brändli, Christof. "abc Technologies 2004 Basel (Switzerland), January 22–23, 2004." CHIMIA International Journal for Chemistry 58, no. 3 (March 1, 2004): 163–65. http://dx.doi.org/10.2533/000942904777678190.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

VOGT, Rudolf. "The Wettstein Bridge over the Rhine at Basel, Switzerland." IABSE Congress Report 16, no. 19 (January 1, 2000): 498–505. http://dx.doi.org/10.2749/222137900796299048.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Voors, Duveken. "A New Perspective—WONCA Europe Conference 2009, Basel, Switzerland." InnovAiT: Education and inspiration for general practice 3, no. 7 (June 18, 2010): 427–28. http://dx.doi.org/10.1093/innovait/inp248.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Glasstetter, Michèle. "Earthworm diversity in urban habitats of Basel (Northwestern Switzerland)." Zoology in the Middle East 58, sup4 (January 2012): 95–102. http://dx.doi.org/10.1080/09397140.2012.10648989.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Thierfelder, Clara, Catherine Schill, Christoph Hatz, and Reto Nüesch. "Trends in Imported Malaria to Basel, Switzerland: Table 1." Journal of Travel Medicine 15, no. 6 (November 1, 2008): 432–36. http://dx.doi.org/10.1111/j.1708-8305.2008.00251.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Masterson, Philip John. "IBC – Proteomics, 1–2 March 2000, Basel Hilton, Switzerland." Comparative and Functional Genomics 2, no. 3 (2001): 180–85. http://dx.doi.org/10.1002/cfg.80.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

SCHMUTZ, C., D. BURKI, R. FREI, M. MÄUSEZAHL-FEUZ, and D. MÄUSEZAHL. "Testing for Chlamydia trachomatis: time trends in positivity rates in the canton of Basel-Stadt, Switzerland." Epidemiology and Infection 141, no. 9 (November 19, 2012): 1953–64. http://dx.doi.org/10.1017/s0950268812002567.

Full text
Abstract:
SUMMARYNational health statistics report a 2·5-fold increase in laboratory-confirmed Chlamydia trachomatis (CT) cases over the last decade in Switzerland where no CT screening programme exists. We obtained essential denominator information to describe the epidemiology of CT in the canton of Basel-Stadt, an urban canton in north-western Switzerland. Laboratories reporting at least two CT infections from Basel-Stadt residents to the SFOPH in 2010 provided demographic and test-related data. CT positivity rates were calculated for 2002–2010. The influences of test year, age, sex and laboratory on CT positivity were investigated in a multivariable model. Positivity differed between sexes and age groups. In our sample of 32 034 records, female and male CT positivity rates were 4·7% and 11·1%, respectively. Test year was significantly associated with test outcome in the multivariable analysis but no time trend was observed. CT positivity did not change over the past 9 years in Basel-Stadt. In contrast to other European countries without CT screening, we found no evidence that the observed increase of Chlamydia cases in the national notification system represents an epidemiological trend, but rather results from an increased testing frequency.
APA, Harvard, Vancouver, ISO, and other styles
28

Obergfell, Eva Inés. "9th International Seminar “Art & Law” for Doctorate Candidates (Basel, Switzerland, July 6–9, 2007)." International Journal of Cultural Property 15, no. 4 (November 2008): 413–15. http://dx.doi.org/10.1017/s094073910808034x.

Full text
Abstract:
Under the auspices of Kurt Siehr (Hamburg, Zürich) the 9th International Seminar on “Art & Law” took place from July 6–9, 2007, in Basel, Switzerland. Originally conceived as a platform for doctorate candidates in Europe and over the last years enlarged to a platform for comprehensive discussions between lawyers as well as art historians, academics as well as practitioners, this year's seminar in Basel focused on three main issues: protection of cultural property, problems of stolen works of art (both including their international and European legal frame), and copyright protection.
APA, Harvard, Vancouver, ISO, and other styles
29

Weingrill, Cleide O., Wania Mussio, Carlinês R. S. Moraes, Evandro Portes, Rita C. Castro, and Ana-Maria J. Lengyel. "Long-acting oral bromocriptine (Parlodel SRO)**Parlodel SRO, Sandoz, Basel, Switzerland. in the treatment of hyperprolactinemia††Supported in part by Sandoz, Basel, Switzerland." Fertility and Sterility 57, no. 2 (February 1992): 331–35. http://dx.doi.org/10.1016/s0015-0282(16)54840-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Wei, Xuntong. "Impact of a Development-Oriented Summer Camp in Shifting Ways in Which Left-behind Children Describe Social Relationships." Lecture Notes in Education Psychology and Public Media 46, no. 1 (April 19, 2024): 6–11. http://dx.doi.org/10.54254/2753-7048/46/20230570.

Full text
Abstract:
Elena Parra-Gonzalez, M., Lopez Belmonte, J., Segura-Robles, A., & Fuentes Cabrera, A. (2020). Active and Emerging Methodologies for Ubiquitous Education: Potentials of Flipped Learning and Gamification. Sustainability (Basel, Switzerland), 12(2), 602. https://doi.org/10.3390/su12020602
APA, Harvard, Vancouver, ISO, and other styles
31

Kulasekararaj, Austin, Guangsheng He, Talha Munir, Jeffrey Pu, Antonio Risitano, Alexander Röth, Camelia S. Sima, et al. "Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 2 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Not Previously Treated with Complement Inhibitors." Blood 136, Supplement 1 (November 5, 2020): 34. http://dx.doi.org/10.1182/blood-2020-136647.

Full text
Abstract:
Background Crovalimab is a novel anti-human complement component 5 (C5) antibody engineered to significantly extend half-life and enable subcutaneous (SC) administration once every 4 weeks in C5-mediated diseases. Based on the promising results of the Phase I/II COMPOSER trial (NCT03157635; Röth et al. Blood. 2020), crovalimab is currently under investigation as a potential therapy for paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening disorder characterized by hemolytic anemia and thrombosis. Eculizumab and ravulizumab are C5 inhibitors currently approved for the treatment of patients with PNH, yet treatment limitations include breakthrough hemolysis due to unsustained C5 inhibition, lack of efficacy in patients with C5 mutational variants, and the treatment burden of regular intravenous (IV) infusions. Study Design and Methods The Phase III, randomized, open-label, active-controlled, multicenter COMMODORE 2 study (NCT04434092) is evaluating the efficacy and safety of crovalimab compared with eculizumab in patients aged ≥ 12 years with PNH not previously treated with complement inhibitors. Patients are randomized 2:1 to receive crovalimab or eculizumab (Figure 1). Two hundred patients in the crovalimab arm will receive a loading series of crovalimab (IV dose on Day 1, followed by weekly SC doses for 4 weeks starting on Day 2). This is followed by SC maintenance dosing every 4 weeks starting at Week 5. Patients in the eculizumab arm receive a weekly IV loading dose of eculizumab for the first 4 weeks, followed by IV maintenance dosing starting at Week 5 and then once every 2 weeks for 24 weeks. After 24 weeks of treatment, patients can continue crovalimab or switch from eculizumab to crovalimab if their physician determines this is in their best interest. The primary efficacy objective of COMMODORE 2 is to evaluate the noninferiority of crovalimab compared with eculizumab based on the co-primary endpoints of (1) the proportion of patients who achieve transfusion avoidance and (2) the proportion of patients with hemolysis control. Secondary efficacy objectives are to evaluate the noninferiority of crovalimab compared with eculizumab in regard to the (1) proportion of patients who experience breakthrough hemolysis, (2) proportion of patients who achieve stabilization of hemoglobin, and (3) mean change in fatigue, as assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire. The safety objective is to evaluate the safety and tolerability of crovalimab compared with eculizumab based on the incidence and severity of adverse events, including infections (meningococcal meningitis and other infections), injection-site reactions, infusion-related reactions, hypersensitivity, and adverse events leading to study drug discontinuation. Pharmacokinetic, immunogenicity, biomarker, and health status utility objectives will also be assessed. Disclosures Kulasekararaj: Alexion Pharmaceuticals Inc.: Honoraria, Membership on an entity's Board of Directors or advisory committees. He:F. Hoffmann-La Roche: Consultancy, Other: Medical writing support, furnished by Scott Battle, PhD, of Health Interactions, was funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland; LongBio Pharma: Consultancy, Research Funding. Munir:F. Hoffmann-La Roche: Consultancy, Other: Medical writing support, furnished by Scott Battle, PhD, of Health Interactions, was funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland; Alexion: Honoraria. Pu:SUNY Upstate Medical University: Current Employment; Pennsylvania State University: Patents & Royalties; F. Hoffmann-La Roche Ltd: Other: Medical writing support, furnished by Scott Battle, PhD, of Health Interactions, was funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Risitano:Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Alnylam: Research Funding; Alexion: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Biocryst: Membership on an entity's Board of Directors or advisory committees; Jazz: Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees; Amyndas: Consultancy; Samsung: Membership on an entity's Board of Directors or advisory committees; Achillion: Membership on an entity's Board of Directors or advisory committees; Apellis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Speakers Bureau; RA pharma: Research Funding. Röth:Roche: Consultancy, Honoraria, Research Funding; Apellis: Consultancy, Honoraria; Alexion Pharmaceuticals Inc.: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Biocryst: Consultancy, Honoraria. Sima:F. Hoffmann-La Roche Ltd/Genentech: Current Employment, Current equity holder in publicly-traded company, Other: Medical writing support, furnished by Scott Battle, PhD, of Health Interactions, was funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Appius:F. Hoffmann-La Roche Ltd: Current Employment, Current equity holder in publicly-traded company, Other: Medical writing support, furnished by Scott Battle, PhD, of Health Interactions, was funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Sostelly:F. Hoffmann-La Roche Ltd: Current Employment, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Sreckovic:F. Hoffmann-La Roche Ltd: Current Employment, Other: All authors received support for third-party writing assistance, furnished by Scott Battle, PhD, provided by F. Hoffmann-La Roche, Basel, Switzerland.. Vignal:F. Hoffmann-La Roche Ltd: Current Employment, Current equity holder in publicly-traded company, Other: Medical writing support, furnished by Scott Battle, PhD, of Health Interactions, was funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Nishimura:Alexion: Honoraria, Research Funding; Chugai: Membership on an entity's Board of Directors or advisory committees; F. Hoffmann-La Roche Ltd: Membership on an entity's Board of Directors or advisory committees, Other: Medical writing support, furnished by Scott Battle, PhD, of Health Interactions, was funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
APA, Harvard, Vancouver, ISO, and other styles
32

Gabi, Simone, Alain Thierstein, Christian Kruse, and Lars Glanzmann. "Governance Strategies for the Zrich-Basel Metropolitan Region in Switzerland." Built Environment 32, no. 2 (June 1, 2006): 157–71. http://dx.doi.org/10.2148/benv.32.2.157.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Timor-Tritsch, Ilan E. "Fetus as a patient, basel switzerland, june 13–15, 1997." Journal of Maternal-Fetal and Neonatal Medicine 7, no. 3 (January 1998): 162. http://dx.doi.org/10.3109/14767059809020434.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Czernin, S., M. Vogel, J. C. Bourgnon, F. Muheim, M. Reichelt, and G. Stoppe. "PW01-257 - Direct costs of suicide attempts in Basel, Switzerland." European Psychiatry 25 (2010): 1685. http://dx.doi.org/10.1016/s0924-9338(10)71664-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Timor-Tritsch, Ilan E. "Fetus as a patient, Basel Switzerland, June 13-15, 1997." Journal of Maternal-Fetal Medicine 7, no. 3 (May 1998): 162. http://dx.doi.org/10.1002/(sici)1520-6661(199805/06)7:3<162::aid-mfm12>3.0.co;2-j.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Arı, Asım. "Secondary Education in Basel, Switzerland: Equipping Youth for University Success." International Journal of Instruction 16, no. 4 (October 1, 2023): i—iv. http://dx.doi.org/10.29333/iji.2023.1640a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Ari, Asim. "A Good Start to School Life, Switzerland Basel Primary Schools." International Journal of Instruction 16, no. 2 (April 1, 2023): i—vi. http://dx.doi.org/10.29333/iji.2023.1620a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Hüglin, Sophie, and Norbert Spichtig. "War Crime or Élite Burial: Interpretations of Human Skeletons Within the Late La Tène Settlement Basel-Gasfabrik, Basel, Switzerland." European Journal of Archaeology 13, no. 3 (2010): 313–35. http://dx.doi.org/10.1177/1461957110386772.

Full text
Abstract:
The case study presents completely different interpretations of the same archaeological evidence. Reasons for that are not only the state of knowledge and the possibilities of research, but also the impact of changes in the socio-political climate and varying theoretical traditions. The examples are taken from the Late La Tène settlement Basel-Gasfabrik, which has been excavated for almost 100 years. The study focuses on a number of more or less complete human skeletons from sunken features inside the settlement. This phenomenon prompted the archaeologists to find explanations for this apparent exception to the ancient rule of burying the dead outside the settlements. The interpretations of this ‘abnormal' burial practice range from victims of war to burials of the members of the élite. The discussion continues on the basis of the synopsis of all verifiable options of dealing with the dead and includes evidence from similar sites elsewhere.
APA, Harvard, Vancouver, ISO, and other styles
39

Lang, Kerstin, and Hugo Bachmann. "On the Seismic Vulnerability of Existing Buildings: A Case Study of the City of Basel." Earthquake Spectra 20, no. 1 (February 2004): 43–66. http://dx.doi.org/10.1193/1.1648335.

Full text
Abstract:
In order to assess the seismic risk for Switzerland, and particularly for the city of Basel, the seismic vulnerability of the existing buildings needs to be evaluated. Since no major damaging earthquake has occurred in Switzerland in recent times, vulnerability functions from observed damage patterns are not available. A simple evaluation method based on engineering models of the building structures suitable for the evaluation of a larger number of buildings is therefore proposed. The method is based on a nonlinear static approach acknowledging the importance of the nonlinear deformation capacity of the buildings subjected to seismic action. Eighty-seven residential buildings in a small target area in Basel were evaluated. The results are vulnerability functions that express the expected damage as a function of the spectral displacement. In order to extrapolate the results to other residential areas of the town, building classes were defined for which the vulnerability is presented in a probabilistic form that can be used directly for earthquake scenario projects.
APA, Harvard, Vancouver, ISO, and other styles
40

Pešić, Vladimir. "A list of water mite types transferred from the Museum of the Natural History in Podgorica and deposited in other museums." Ecologica Montenegrina 49 (December 25, 2021): 88–94. http://dx.doi.org/10.37828/em.2021.49.8.

Full text
Abstract:
A list of the water mites (Acari, Hydrachnidia) types originally stated to be deposited in the Museum of Natural History in Montenegro, Podgorica, Montenegro and later on transferred to Museum of Natural History in Basel (Switzerland) and Naturalis Biodiversity Center in Leiden (the Netherlands) is given.
APA, Harvard, Vancouver, ISO, and other styles
41

Liechtenstein, Stephanie. "The 21st osce Ministerial Council Meeting in Basel." Security and Human Rights 25, no. 4 (December 31, 2014): 406–39. http://dx.doi.org/10.1163/18750230-02504009.

Full text
Abstract:
This article analyses the outcome of the 21stosce Ministerial Council (mc) meeting, held in Basel, Switzerland, on 4 and 5 December 2014. The larger political context is taken into account, especially the crisis in and around Ukraine and the renewed confrontation between the West and Russia. The article provides an extensive analysis of all adopted decisions in the three security dimensions as well as of a number of draft documents that failed to reach consensus. The main documents that are analyzed include declarations on the Helsinki+40 process and on protracted conflicts, and decisions on countering kidnapping for ransom and terrorist foreign fighters, preventing corruption, improving disaster risk reduction, and on combating violence against women. The article concludes that the Swiss osce Chairmanship helped to reaffirm the osce’s role as the main forum for political dialogue between East and West.
APA, Harvard, Vancouver, ISO, and other styles
42

Huh, Hee Jae, Won-Jung Koh, Dong Joon Song, Chang-Seok Ki, and Nam Yong Lee. "Evaluation of the Cobas TaqMan MTB Test for the Detection of Mycobacterium tuberculosis Complex According to Acid-Fast-Bacillus Smear Grades in Respiratory Specimens." Journal of Clinical Microbiology 53, no. 2 (November 26, 2014): 696–98. http://dx.doi.org/10.1128/jcm.02630-14.

Full text
Abstract:
We evaluated the performance of the Cobas TaqMan MTB test (Roche Diagnostics, Basel, Switzerland), stratified by acid-fast bacilli (AFB) smear grades. The sensitivity of this test in smear-positive specimens was >95% in all grades, while that in trace and negative specimens was 85.3% and 34.4%, respectively.
APA, Harvard, Vancouver, ISO, and other styles
43

Nana Opare Kwakye, Abraham. "Returning African Christians in Mission to the Gold Coast." Studies in World Christianity 24, no. 1 (April 2018): 25–45. http://dx.doi.org/10.3366/swc.2018.0203.

Full text
Abstract:
The transatlantic slave trade created an African diaspora in the Western world. Some of these diaspora Africans encountered and embraced the religion of their Western masters. Life in the Caribbean diaspora provided an opportunity for the nestling of ideas that were to shape the establishment of the Christian faith in Africa. Following the failures of European missionaries to make an impact in Africa in the early nineteenth century, freshly emancipated Christians from the Caribbean became agents of social transformation in the Gold Coast, Cameroun and Nigeria. Using archival records from Basel in Switzerland and Ghana, this paper explores the missionary initiative of Jamaican Christians who worked under the aegis of the Basel Evangelical Missionary Society from 1843 to 1918. It provides evidence that these Jamaican Christians became principal agents for the success of the Basel Mission's enterprise in the Gold Coast in the nineteenth century. The paper argues against a Eurocentric approach to mission historiography that has obviated the roles of Africans in the nineteenth century and demonstrates the legacy which these returning Africans have left the church in Africa.
APA, Harvard, Vancouver, ISO, and other styles
44

Hamdi, R., and G. Schayes. "Validation of Martilli's urban boundary layer scheme with measurements from two mid-latitude European cities." Atmospheric Chemistry and Physics 7, no. 17 (August 31, 2007): 4513–26. http://dx.doi.org/10.5194/acp-7-4513-2007.

Full text
Abstract:
Abstract. Martilli's urban parameterization scheme is improved and implemented in a mesoscale model in order to take into account the typical effects of a real city on the air temperature near the ground and on the surface exchange fluxes. The mesoscale model is run on a single column using atmospheric data and radiation recorded above roof level as forcing. Here, the authors validate Martilli's urban boundary layer scheme using measurements from two mid-latitude European cities: Basel, Switzerland and Marseilles, France. For Basel, the model performance is evaluated with observations of canyon temperature, surface radiation, and energy balance fluxes obtained during the Basel urban boundary layer experiment (BUBBLE). The results show that the urban parameterization scheme represents correctly most of the behavior of the fluxes typical of the city center of Basel, including the large heat uptake by the urban fabric and the positive sensible heat flux at night. For Marseilles, the model performance is evaluated with observations of surface temperature, canyon temperature, surface radiation, and energy balance fluxes collected during the field experiments to constrain models of atmospheric pollution and transport of emissions (ESCOMPTE) and its urban boundary layer (UBL) campaign. At both urban sites, vegetation cover is less than 20%, therefore, particular attention was directed to the ability of Martilli's urban boundary layer scheme to reproduce the observations for the Marseilles city center, where the urban parameters and the synoptic forcing are totally different from Basel. Evaluation of the model with wall, road, and roof surface temperatures gave good results. The model correctly simulates the net radiation, canyon temperature, and the partitioning between the turbulent and storage heat fluxes.
APA, Harvard, Vancouver, ISO, and other styles
45

Hugonnet, S., Hugo Sax, and D. Pittet. "Management of viral haemorrhagic fevers in Switzerland." Eurosurveillance 7, no. 3 (March 1, 2002): 42–44. http://dx.doi.org/10.2807/esm.07.03.00340-en.

Full text
Abstract:
Over the past years, there have been very few imported cases of VHF in Switzerland: one confirmed and four suspected cases of Ebola fever in Basel in 1994, two suspected cases of Ebola and Lassa fevers in Lausanne in 2000, and in the same year, six suspected cases of Lassa fever in Geneva. Given the considerable diversity in the management of patients with suspected or confirmed VHF, national guidelines are needed, as well as the establishment of a national reference centre.
APA, Harvard, Vancouver, ISO, and other styles
46

Bergquist, Robert, and Lukas Meier. "Marcel Tanner, Global Health Specialist “Extraordinaire” Incl Supplementary Materials with Personal Contributions from Renowned Experts." Diseases 10, no. 4 (September 30, 2022): 74. http://dx.doi.org/10.3390/diseases10040074.

Full text
Abstract:
Marcel Tanner, President of the Swiss Academy of the Sciences, Director emeritus of the Swiss Tropical and Public Health Institute (Swiss TPH), and Professor of Epidemiology and Medical Parasitology at the University of Basel, Switzerland, is indeed extraordinary, especially when considering the broad set of global health issues covered by his research [...]
APA, Harvard, Vancouver, ISO, and other styles
47

Wicki, Andreas, Eberhard Parlow, and Christian Feigenwinter. "Evaluation and Modeling of Urban Heat Island Intensity in Basel, Switzerland." Climate 6, no. 3 (June 21, 2018): 55. http://dx.doi.org/10.3390/cli6030055.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Kuhne, Thomas, Alain Di Gallo, Pierino Avoledo, Paul Imbach, Dietrich von Schweinitz, and Fritz Hefti. "PEDIATRIC HEMATOLOGY AND ONCOLOGY AT THE UNIVERSITY CHILDREN'S HOSPITAL, BASEL, SWITZERLAND." Pediatric Hematology and Oncology 17, no. 1 (January 2000): 15–19. http://dx.doi.org/10.1080/088800100276622.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Kulbe, Klaus D., and Roland Wohlgemuth. "The Eleventh European Congress on Biotechnology, Basel, Switzerland, August 26, 2003." Biocatalysis and Biotransformation 22, no. 2 (March 2004): 61–62. http://dx.doi.org/10.1080/10242420410001710074.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Wicki, Melanie, Paul Svoboda, and Marcel Tanner. "Occurrence of Giardia lamblia in recreational streams in Basel-Landschaft, Switzerland." Environmental Research 109, no. 5 (July 2009): 524–27. http://dx.doi.org/10.1016/j.envres.2009.02.012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Rehab Basel (Basel, Switzerland)' for other source types:
Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography